MRS to Determine Neuroinflammation and Oxidative Stress in MPS I

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-01

Study Completion Date

2019-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Neuroinflammation and oxidative stress have been shown to be present in persons with mucopolysaccharidosis type I (MPS I), but their effect on disease severity and disease progression is unknown. The investigator intends to employ brain magnetic resonance spectroscopy (MRS), a non-invasive technique, along with analysis of neuroinflammation and oxidative stress biomarkers in the blood, to measure and determine the level of oxidative stress and neuroinflammation, and their impact on clinical variability in MPS I patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Muscle Oxidative Capacity Relationship With Muscular Endurance, Fatigue (Multiple Sclerosis).

NCT06083194

Multiple Sclerosis

UNKNOWN

Magnetic Resonance & Optical Spectroscopy Validation

NCT01827527

Validation Studies Magnetic Resonance Spectroscopy

RECRUITING

Non-Invasive Monitoring Of Metabolite Levels Using Novel And Adapted MR Spectroscopy Techniques

NCT05165537

Magnetic Resonance Spectroscopy

RECRUITING NA

Neurometabolic Profile of Individuals With Primary Mitochondrial Disease

NCT06890520

Primary Mitochondrial Disease

RECRUITING

Quantifying Myofascial Dysfunction in Post-Stroke Pain

NCT05762679

Myofascial Dysfunction

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Persons with MPS I have a wide range of clinical manifestations including central nervous system (CNS) impairment. The role of neuroinflammation and oxidative stress is one avenue of investigation which may clarify the broad neurological impairment in MPS I. Finding biomarkers that accurately describe the underlying and ongoing brain pathology is a key not only to understanding the disease, but also to understanding the possibility of new therapeutic approaches for MPS I patients.

The investigator will compare patients with Hurler syndrome, and Hurler-Scheie or Scheie syndrome, with healthy controls. There will be 10 participants in each group, resulting in a total of 30 participants. Within the Hurler-Scheie or Scheie syndrome group, the investigator will examine the association of clinical severity with the proposed measures. These findings might help determine whether hematopoietic cell transplantation (HCT), which is the treatment for Hurler syndrome patients, results in decreased oxidative stress and neuroinflammation as compared to Hurler-Scheie or Scheie syndrome patients, who are treated by enzyme replacement therapy (ERT). Additionally, these findings might help determine whether therapies directed at reducing neuroinflammation and oxidative stress in MPS I could enhance neurological outcomes.

Study hypothesis: neuroinflammation and oxidative stress are present in MPS I subjects and are reflective of disease severity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mucopolysaccharidosis Type I

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hurler syndrome participants

Participants who have MPS IH, also called Hurler syndrome

No interventions assigned to this group

Hurler-Scheie/Scheie participants

Participants who have either MPS IHS or MPS IS. MPS IHS is also called Hurler-Scheie syndrome. MPS IS is also called Scheie syndrome.

No interventions assigned to this group

Healthy Controls

Age-matched healthy controls

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

MPS I participants must meet the following:

1. Diagnosis of Hurler syndrome, OR Hurler-Scheie syndrome, OR Scheie syndrome
2. 6 years of age or older at time of screening

Healthy control participants must meet all of the following:

1. Absence of neurological disorder
2. 6 years of age or older at time of screening

Exclusion Criteria

Persons who have any of the following will not be enrolled in this study:

1. Any surgically implanted pacemaker
2. Any indwelling electronic device, including programmable shunts
3. Orthodontic braces, unless non-metallic
4. Other implanted metal in the body other than titanium
5. An inability or unwillingness to complete an MRI/MRS because of low cognitive function or behavioral dysregulation
6. Pregnancy

Minimum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes